Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Dextroamphetamine

Plain-language summaryIntrigue 65 / 100

Dextroamphetamine is the d-enantiomer of amphetamine, sold as Dexedrine since 1976. The d-form is roughly two to three times more potent at central dopamine release than the l-form, while both release norepinephrine about equally. The practical result is a stimulant tilted toward CNS dopamine effects with somewhat less peripheral cardiovascular load than racemic mixtures like Adderall. Approved for ADHD and narcolepsy. Schedule II. Used clinically when patients tolerate racemic amphetamine poorly and as the canonical pure d-amphetamine reference in research where investigators need to isolate the dopaminergic component of the response. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

41/100

Canonical d-amphetamine reference compound; settled pharmacology, limited frontier value, probe utility only

Dextroamphetamine is about as well-characterized as a compound gets in psychopharmacology. FDA approved in 1976, used clinically for ADHD and narcolepsy for nearly five decades; the literature here is enormous, the mechanism is settled, and the basic pharmacology has been picked over thoroughly. Thats not a knock on the compound: it’s just the reality of its place in the field.

The core story is well-known: d-amphetamine is approximately 2-3x more potent at central dopamine release than the l-enantiomer, while both enantiomers release norepinephrine at roughly equivalent rates. The net pharmacological profile versus racemic amphetamine is a cleaner CNS dopaminergic signal with reduced peripheral sympathomimetic activity. Mechanistically, this is monoamine reverse-transport via DAT, NET, and SERT: textbook amphetamine pharmacology, not something new.

Where it does retain value is as a research probe for pure d-amphetamine pharmacology. If you’re studying enantiomeric contributions to amphetamine effects, comparing d- versus l-amphetamine release dynamics, or using it as a reference standard in translational ADHD models, dextroamphetamine is the canonical compound. There’s no substitute for that specific role. The bench value score reflects this: genuinely useful in a narrow but legitimate context.

What we don’t love is that the interesting amphetamine-adjacent research isn’t really about dextroamphetamine per se anymore. The questions the field actually cares about now involve TAAR1 agonism and its emerging role in monoamine homeostasis, the pharmacogenomics of amphetamine response variability, and dual dopamine-serotonin releasers as novel depression targets. Dextroamphetamine is background context for those conversations, not the interesting variable in them. The differentiation score is modest for good reason: it’s the canonical probe, but the probe itself isn’t what’s being investigated.

Evidence quality is objectively high. This is an approved drug with extensive phase 3 data, multi-decade replication across independent labs, and clear translational signal for ADHD and narcolepsy. But high evidence quality for settled questions doesn’t make a compound compelling as a bench research target; it makes it a reference standard, which is a different thing entirely.

The Schedule II classification adds real logistical friction. DEA licensing, handling requirements, institutional overhead: none of this is insurmountable, but it shapes what a lab is actually going to reach for when designing a study. Combined with the saturation of the literature, there are very few questions a serious bench lab would be trying to answer with dextroamphetamine that haven’t already been answered decades ago. Honestly, it earns its score as a historical anchor and occasional enantiomeric probe; it doesnt earn more than that.

Novelty

10

Mechanism promise

20

In-category differentiation

35

Evidence quality

75

Translational signal

75

Research bench value

55

Rationale Decades-old Schedule II compound with thoroughly settled dopaminergic mechanism; scores high on evidence quality and translational signal for its approved indications but very low on novelty and differentiation, producing a moderate overall that reflects reference-standard status rather than active research frontier. Schedule II cap of 65 does not bind since calculated overall is 41.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

d-enantiomer amphetamine (dopaminergic-preferring)

The d-enantiomer of amphetamine; a more dopaminergic stimulant than the racemic mixture, used in ADHD and narcolepsy.

Abstract

Dextroamphetamine ((S)-1-phenylpropan-2-amine, d-amphetamine; CAS 51-64-9; molecular formula C9H13N; molecular weight 135.21) is the d-enantiomer of amphetamine, approved by the FDA in 1976 (Dexedrine). The d-enantiomer is approximately 2 to 3 fold more potent at central dopamine release than the l-enantiomer; both enantiomers have approximately equivalent norepinephrine release. The pharmacology versus racemic amphetamine is shifted toward CNS dopaminergic effects with reduced peripheral cardiovascular activity. Approved indications: ADHD, narcolepsy. Plasma half-life is approximately 12 hours. Schedule II. Used as the canonical pure d-amphetamine in research and clinical practice for patients tolerating racemic amphetamine poorly.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-380Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Citrulline Malate

Plain-language summaryIntrigue 55 / 100

Citrulline malate combines L-citrulline (an amino acid your kidneys convert into L-arginine) with malic acid (a TCA cycle intermediate). The trick is that citrulline supplementation actually raises blood arginine more effectively than arginine itself, because it bypasses the intestinal arginase enzyme that destroys most oral arginine before it reaches circulation. Higher arginine fuels nitric oxide synthesis (vasodilation, the famous pre-workout pump) and supports urea cycle ammonia clearance. The malate component helps keep TCA-driven ATP production running. Standard pre-workout dosing is 6 to 10 g taken 60 to 90 minutes before exercise, with reasonable evidence for increased resistance training volume and reduced post-workout soreness. Among the more credible pre-workout ingredients. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Well-understood pre-workout ingredient with solid exercise evidence but zero research novelty

Look, citrulline malate is one of those compounds where the science is basically done. The mechanism is completely mapped: L-citrulline converts to L-arginine in the kidneys, bypassing intestinal arginase, which degrades oral arginine before it reaches systemic circulation. That salvaged arginine then feeds nitric oxide synthase, driving vasodilation. The malate portion is a TCA cycle intermediate that supports aerobic ATP production and likely buffers ammonia accumulation during high-intensity work. Clean mechanism, understood for over two decades, nothing surprising here.

The evidence base is actually solid by supplement standards. Multiple RCTs have confirmed effects on resistance training volume, and there’s reasonably consistent data on reduced post-exercise muscle soreness across independent labs. The Perez-Guisado work and subsequent replications are well-documented in exercise physiology. We’re not talking about single-lab work or marketing claims dressed as research. The human translational signal is real and repeatable.

What kills the score is that none of this is interesting anymore. A bench scientist in 2026 is not reaching for citrulline malate as a research target. The NO pathway is saturated territory. The urea cycle angle has been thoroughly mapped. There is no novel indication space, no unexplored mechanism, no surprising biology to chase. The malate contribution specifically is contested: it’s not clear how much malic acid at standard pre-workout doses actually shifts TCA flux in exercising muscle, and the literature hasn’t convincingly resolved whether the 2:1 complex outperforms plain L-citrulline in any meaningful way. Nobody is writing grants to find out.

As a research tool, citrulline malate has essentially no probe value. If you want to study NO biology, you’d reach for L-NAME or well-characterized NOS inhibitors. If you want urea cycle work, there are purpose-built tools. The compound’s entire identity is pre-workout ingredient, and thats not what serious investigators are doing bench work on.

Differentiation is a problem too. The case for citrulline malate over plain L-citrulline rests primarily on industry framing. The malate may contribute something, but evidence that the specific complex has a scientifically meaningful edge over the amino acid alone is thin. You’re stacking two understood, unremarkable metabolites and hoping the combination exceeds the sum.

Honest assessment: this belongs in a sports nutrition product. We stock it because the exercise science is clean and it has utility in protocols where NO pathway manipulation is needed as a straightforward control condition. But it shouldn’t occupy any serious investigator’s attention in 2026.

Novelty

16

Mechanism promise

28

In-category differentiation

25

Evidence quality

58

Translational signal

55

Research bench value

22

Rationale Both L-citrulline and malic acid are fully characterized molecules with mapped pharmacology; the combination has decent RCT support for exercise performance but no novel mechanism, unexplored indication space, or meaningful bench utility to recommend it as a priority research target in 2026.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Amino acid + organic acid (NO precursor / TCA cycle support)

L-citrulline complexed with malic acid; a nitric oxide precursor (via arginine) and TCA cycle substrate used in pre-workout supplements.

Abstract

Citrulline malate (L-citrulline DL-malate, CAS 70796-17-7; complex of L-citrulline (CAS 372-75-8, C6H13N3O3, MW 175.19) and malic acid (CAS 6915-15-7, C4H6O5, MW 134.09); commercial 2:1 or 1:1 ratios) is a complex of the amino acid L-citrulline with malic acid. L-citrulline is converted in the kidneys to L-arginine, the substrate for nitric oxide synthase; circulating arginine produced from citrulline supplementation is paradoxically more effective than direct arginine supplementation owing to the bypass of intestinal arginase. The malic acid portion is a TCA cycle intermediate supporting aerobic ATP production. Combined, the compound improves exercise performance through vasodilation (nitric oxide-mediated), reduced ammonia accumulation (urea cycle support), and ATP production. Plasma half-life of citrulline is approximately 1 hour. Used widely in pre-workout supplements (8 to 10 g doses, 60 to 90 minutes pre-exercise) with documented effects on resistance training volume and reduced post-exercise soreness.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-396Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
CX-614

Plain-language summaryIntrigue 40 / 100

CX-614 is another benzoxazine ampakine in the Cortex series. Investigated in early clinical trials for cognitive impairment. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

42/100

Potent AMPA probe with real bench utility but no translational path and a stalled class

CX-614 is a benzoxazine ampakine out of the Cortex Pharmaceuticals program that ran through the late 1990s and 2000s alongside CX-516 and CX-546. The compound is legitimately interesting as a probe: its roughly 100-fold potency advantage over CX-516 in AMPA receptor potentiation assays isn’t marketing noise, it shows up consistently in comparative cellular work. If you’re running BDNF induction studies and want pharmacological control over AMPA throughput without saturating concentrations, CX-614 is a real tool.

The BDNF upregulation story is the most compelling part of the science here. Chronic ampakine treatment drives hippocampal BDNF expression through transcriptional mechanisms downstream of AMPA potentiation. This is a legitimate model for studying neurotrophin-mediated synaptic plasticity and it’s been used by multiple independent groups, not just the originating program. That matters. Replication outside Cortex gives the bench utility real credibility and separates CX-614 from single-lab-only probe compounds.

Here’s the thing though: the ampakine class as a therapeutic direction has largely stalled. CX-516 had a small clinical footprint and the results were underwhelming. Seizure risk and excitotoxicity concerns have shadowed every high-potency member of the class. CX-614’s potency, which is an asset on the bench, is a liability from a translational standpoint. That 100-fold number doesnt come with a 100-fold therapeutic window, and there’s no sponsor currently pushing a benzoxazine ampakine through a pipeline.

We dont see a strong path to clinical relevance for CX-614 specifically. The novel angle, AMPA-driven BDNF induction as a tractable route to synaptic plasticity enhancement, remains interesting theoretically, but the pharmacological levers available today include BDNF mimetics, TrkB agonists, and ketamine’s downstream BDNF release mechanism, all of which generate stronger translational signals with more current evidence behind them. The class simply hasn’t rehabilitated itself with more recent data, and CX-614 inherits that problem.

What CX-614 does well is narrow but real: it’s a high-potency probe for dissecting AMPA receptor contributions to BDNF signaling in controlled in vitro and rodent systems. If thats the question you’re asking, honestly, it earns a spot in the toolkit. If you’re looking for a compound that carries a compelling story toward clinical translation or opens a genuinely new mechanistic frontier, there are better candidates right now. The score reflects a compound that occupies a legitimate but limited niche: not junk, not boring, but not the compound you build a program around in 2026.

Novelty

38

Mechanism promise

48

In-category differentiation

45

Evidence quality

42

Translational signal

22

Research bench value

62

Rationale CX-614 earns its place as a legitimate preclinical probe for AMPA-mediated BDNF induction, with multi-lab use validating the bench utility score; however, the ampakine class has largely failed to translate and CX-614 itself has never entered human trials, keeping translational and novelty scores low and pulling the overall to the low 40s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Benzoxazine ampakine

A potent benzoxazine ampakine with research applications in BDNF upregulation and synaptic plasticity studies.

Abstract

CX-614 (2H,3H,6aH-pyrrolidino-[2,1-3′,2′]1,3-oxazino-[6′,5′-5,4]benzo[e]1,4-dioxan-10-one; CAS 215923-55-0; molecular formula C16H17NO4; molecular weight 287.32) is a potent benzoxazine-class ampakine developed at Cortex Pharmaceuticals as part of the same program that produced CX-516 and CX-546. CX-614 shows substantially higher AMPA potentiation potency than CX-516 in cellular assays (approximately 100-fold greater per molecule). The compound has been used extensively as a research probe for BDNF upregulation studies; chronic ampakine treatment elevates hippocampal BDNF expression through transcriptional mechanisms downstream of AMPA potentiation, providing a pharmacological model for neurotrophin-mediated synaptic plasticity. CX-614 has not been advanced to human clinical trials. The compound is sold as a research chemical with limited availability.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-056Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Nebracetam

Plain-language summaryIntrigue 30 / 100

Nebracetam is a phenyl-aminomethyl pyrrolidinone racetam developed in Japan. It is reported to enhance acetylcholine release through different mechanisms than other racetams. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

Discontinued 1980s racetam with a real M1 twist but no active research community and better probes now available

Look, nebracetam is one of those 1980s Japanese pharma experiments that had a real idea behind it and then got quietly shelved. Daiichi took the piracetam scaffold, dropped a 4-phenyl group onto the pyrrolidinone ring (a structural move similar to phenylpiracetam), and added an aminomethyl modification that introduced something the classical racetams dont have: partial M1 muscarinic acetylcholine receptor agonism. That’s a legitimately different pharmacological profile. M1 selectivity has been a persistent goal in cholinergic CNS pharmacology, and nebracetam gets part of the way there without tipping into the full agonist territory that caused the older M1 programs so much trouble.

The problem is thats where the story peaks. The Phase 2 program in mild cognitive impairment and elderly memory disorders came back positive but modest, and Daiichi discontinued. We dont have a clean public record of exactly why. Was it effect size? A subtle safety signal at scale? Commercial calculus? That ambiguity is itself informative. Nobody has seriously revisited it since, and the absence of follow-on development from any group in four decades is a meaningful data point against it.

The M1 angle would be more compelling if better probes didn’t now exist. Xanomeline-trospium (Cobenfy) has defined what M1 selective agonism can do in a clinical context, and its mechanistic story is sharper than nebracetam’s partial activity. On the racetam side, phenylpiracetam handles the phenyl-substituted question with more accessible literature and a cleaner investigator community behind it. Nebracetam doesnt obviously beat either of those reference compounds on the bench.

The evidence quality is thin relative to its age. The Phase 2 data exists but was never published in a form thats independently verifiable or widely replicated. The Daiichi-era preclinical work is real but aging, and outside replication is sparse enough that this sits close to single-lab territory even though it technically cleared Phase 2. Thats not nothing, but its not a strong foundation for a 2026 research program.

We’d reach for nebracetam only if we were specifically trying to dissect the M1 component of racetam-class effects and had exhausted better options. That’s a narrow historical question. For modern muscarinic research the selective agonist literature is cleaner; for modern racetam research other analogs have more contemporary traction. Honestly, the score reflects its position accurately: interesting concept, real early clinical signal, discontinued program, no serious modern home.

Novelty

22

Mechanism promise

38

In-category differentiation

22

Evidence quality

33

Translational signal

28

Research bench value

25

Rationale Nebracetam has a genuinely distinct profile from classical racetams via partial M1 muscarinic agonist activity, which is the one thing that makes it interesting, but development was discontinued after modest Phase 2 results and no serious external group has picked it up since. Both the muscarinic and the phenyl-racetam questions it was positioned to answer are now better addressed by other compounds.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenyl-substituted aminomethyl pyrrolidinone

A 4-phenyl-pyrrolidinone with M1 muscarinic receptor agonist activity developed by Daiichi for cognitive impairment, discontinued in development.

Abstract

Nebracetam (WEB-1881-FU; 4-phenyl-2-pyrrolidinone-1-acetamide methyl derivative; CAS 97205-34-0; molecular formula C13H18N2O2; molecular weight 234.30) is a piracetam analog developed by Daiichi Pharmaceutical in Japan in the 1980s with structural features distinct from the classical racetam class. The compound includes a 4-phenyl group on the pyrrolidinone ring (similar to phenylpiracetam) and an aminomethyl modification on the acetamide side chain. Pharmacology shows partial M1 muscarinic acetylcholine receptor agonist activity in addition to the cholinergic facilitation typical of the racetam class. Phase 2 trials in mild cognitive impairment and elderly memory disorders showed positive but modest results; the development program was discontinued and the compound was never approved. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled. Pharmacokinetics include plasma half-life of approximately 4 hours and good oral bioavailability. The clinical evidence base is limited; the M1 muscarinic agonist activity introduces a distinct profile from the open-chain racetams.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-038Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
CX-516 (Ampalex)

Plain-language summaryIntrigue 48 / 100

CX-516 (ampalex) is the first benzoylpyrrolidine ampakine, developed at Cortex Pharmaceuticals. Phase 2 trials in schizophrenia and Alzheimer were inconclusive. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

First-generation AMPA PAM prototype with poor PK and mixed Phase 2 results, now largely superseded by later ampakines

Look, CX-516 matters historically. It was the compound that proved you could take an AMPA receptor positive allosteric modulator into humans and not immediately break things. Gary Lynch’s group at UC Irvine built a real pharmacological hypothesis around AMPA potentiation driving BDNF release and synaptic consolidation, and Cortex Pharmaceuticals ran it all the way through Phase 2 trials. That took real effort and the mechanism story is still interesting. We dont score for effort, though.

Here’s the thing about CX-516’s pharmacokinetics: they’re bad. Half-life around one to two hours, low oral bioavailability, and doses in the clinical trials running from 200 to 1200 mg administered three to four times daily just to maintain any exposure. That dose burden alone tells you this compound wasnt built for translation. The trials in mild cognitive impairment, schizophrenia cognitive symptoms, and fragile X syndrome all produced results that were mixed at best and insufficient to justify Phase 3 advancement. When three different indications each fail to generate a clear signal, the compound’s translational story becomes very hard to defend.

The AMPA PAM mechanism itself still draws serious attention. Positive allosteric modulation of AMPA receptors can enhance synaptic throughput without the direct receptor overstimulation risks of AMPA agonism, and the downstream effects on BDNF and long-term potentiation are mechanistically coherent. But CX-516 is the weakest version of that story. CX-546 has better PK. CX-614 has better receptor kinetics. If you want to run an ampakine experiment in a rodent model today, there are cleaner probes available. CX-516 retains some value as a reference compound for cross-study comparisons with older literature, but that’s a narrow use case.

What we don’t like: a compound that was the first doesn’t stay the best, and here the field moved on pretty decisively. The Phase 2 failures aren’t disqualifying for the mechanism class, but they are disqualifying for CX-516 as a serious research target. The PK liabilities aren’t a minor issue to work around; they’re the reason this compound never graduated.

Honestly, if you’re running an AMPA potentiation research program, CX-516 belongs in your comparison set and your historical context section, not in your primary experimental arm. It’s the compound that opened the door. Later ampakines walked through it. Score reflects that accurately.

Novelty

22

Mechanism promise

48

In-category differentiation

20

Evidence quality

48

Translational signal

28

Research bench value

38

Rationale CX-516 scores low on novelty and differentiation because it is explicitly a superseded first-generation prototype with known pharmacokinetic liabilities; the AMPA PAM mechanism itself is genuinely interesting and partially salvages the mechanism and bench scores, but Phase 2 failures across three indications hold translational signal down, and later compounds in the same class are simply better tools.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Benzoylpyrrolidine ampakine

The first ampakine to enter human clinical trials, developed at Cortex Pharmaceuticals as a mechanism prototype with limited efficacy.

Abstract

CX-516 (Ampalex; 1-(quinoxalin-6-ylcarbonyl)piperidine; CAS 154235-83-3; molecular formula C14H15N3O; molecular weight 241.29) was the first ampakine compound to enter human clinical trials, developed at Cortex Pharmaceuticals (now RespireRx Pharmaceuticals) under license from Gary Lynch and Gary Rogers at the University of California, Irvine. The compound is a benzoylpyrrolidine class AMPA receptor positive allosteric modulator. CX-516 advanced through Phase 2 trials in mild cognitive impairment, schizophrenia (cognitive symptoms), and fragile X syndrome, with mixed results that did not support advancement to Phase 3. The compound has poor pharmacokinetic properties (very short plasma half-life, approximately 1 to 2 hours, and low oral bioavailability) which limit its clinical utility despite mechanistic interest. CX-516 retains research utility as an AMPA potentiator probe but is largely superseded by later-generation compounds (CX-546, CX-614, and others). Doses in clinical trials ranged from 200 to 1200 mg per administration, three to four times daily. The compound is sold as a research chemical in jurisdictions where it is not scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-054Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
IGF-1 LR3

Plain-language summaryIntrigue 65 / 100

IGF-1 LR3 is a long-acting modified form of insulin-like growth factor 1. The R3 modification reduces binding to IGF-binding proteins, extending the half-life from minutes to hours. Used in research contexts for muscle growth studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

43/100

Useful IGF-1R probe with extended half-life but limited novelty and a thin clinical evidence base

Look, IGF-1 LR3 earns its place in a serious lab not because it’s exciting right now, but because it’s the cleanest available probe for IGF-1 receptor biology when extended bioavailability is the requirement. The core engineering is tidy: a 13-residue N-terminal extension combined with Glu-to-Arg substitution at position 3 substantially reduces binding to IGF binding proteins, pushing plasma half-life from roughly 12-15 hours for native IGF-1 to 20-30 hours for LR3. For cell culture work, that extended window matters practically. For in vivo rodent studies, you get more stable receptor occupancy without the dosing burden native IGF-1 imposes. GroPep originally developed it for mammalian cell growth media in the 1990s and that lineage is visible in how it behaves.

That said, the mechanism isnt novel by any stretch. IGF-1R signals through canonical PI3K/Akt/mTOR, and that territory is well-saturated in the literature. We’re not learning anything structurally new about IGF-1 biology by using LR3 that couldn’t be learned with native IGF-1 and careful protocol design. The value here is entirely pharmacokinetic convenience, not mechanistic novelty. The IGFBP-reduction strategy was a real innovation when it was first proposed; in 2026, it’s standard receptor pharmacology.

Where things get complicated is the translational picture. The IGF-1 axis is genuinely important in growth disorders, sarcopenia, and metabolic biology, and theres legitimate investigator interest in how IGF-1 modulation affects muscle protein synthesis and anabolic signaling in aging models. But the clinical base for LR3 specifically is thin. Mecasermin (native IGF-1) has formal regulatory data in severe primary IGF-1 deficiency; LR3 does not have a corresponding trial base. And the chronic-elevation safety concern is real, not precautionary boilerplate: sustained IGF-1 pathway activation is mechanistically connected to increased cancer risk and acromegalic features. That’s not a reason to avoid the compound as a research tool, but it firmly limits how aggressive a chronic-protocol investigator can be.

Differentiation within its niche is reasonable. Des(1-3)IGF-1 competes for some of the same in vitro applications, but LR3 is the dominant form in research catalogs and the more consistently cited analog across cell culture and rodent literature. For investigators specifically probing IGFBP-independent IGF-1R activation, it’s the practical default.

Honestly, we see this in the useful-but-not-urgent tier. Its bench value for IGF-1R biology, muscle research, and metabolic signaling programs is real and not overstated. But novelty is low, the evidence base for systemic investigational use is underdeveloped, and the safety constraints mean no major clinical program is going to be built on LR3 in its current form. Worth stocking for a serious GH-axis or muscle biology program. Dont expect it to anchor a novel research agenda on its own.

Novelty

35

Mechanism promise

40

In-category differentiation

55

Evidence quality

40

Translational signal

35

Research bench value

58

Rationale LR3’s IGFBP-reduction engineering is pharmacokinetically rational and it remains the dominant form for IGF-1R research requiring extended bioavailability, but the underlying mechanism is decades-old canonical PI3K/Akt/mTOR signaling with no novel target; formal human clinical data for the LR3 variant specifically is sparse, and chronic-elevation safety concerns actively constrain translational ambition.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Long Arg3 IGF-1 analog

A long-acting analog of IGF-1 with N-terminal extension and Arg3 substitution that reduces IGFBP binding and extends plasma half-life.

Abstract

IGF-1 LR3 (Long R3 IGF-1; CAS 946870-92-4; molecular weight 9111) is a recombinant analog of human IGF-1 with two structural modifications: a 13-residue N-terminal extension derived from the methionyl-N-terminal region of porcine GH, and substitution of arginine for glutamic acid at position 3. Both modifications reduce binding to IGF binding proteins (IGFBPs), which extends the plasma half-life and increases free bioavailable IGF-1 activity at IGF-1 receptors. The compound was originally developed for cell culture applications (mammalian cell growth media); research-grade availability supports investigational use. Pharmacokinetics: plasma half-life approximately 20 to 30 hours (versus 12 to 15 hours for native IGF-1). The compound is sold as a research chemical at concentrations typically 1 mg/mL. Investigational doses for performance applications range widely (20 to 100 micrograms per day) but the safety profile of long-term IGF-1 elevation is poorly characterized; chronic IGF-1 elevation is implicated in increased cancer risk and acromegalic features.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-087Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Methylene Blue

Plain-language summaryIntrigue 75 / 100

Methylene blue is a phenothiazine dye used historically for malaria, methemoglobinemia, and septic shock. At low doses it serves as an alternative electron donor in mitochondria, supporting energy production when normal pathways are impaired. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

53/100

Old phenothiazine with a genuine low-dose mitochondrial story; speculative cognitive signal but solid bench utility

Look, methylene blue is a weird one. It’s the oldest synthetic pharmaceutical compound still in active use, first synthesized in 1876, and its continued relevance is more interesting than its history suggests. The thing that matters for modern research isn’t the methemoglobinemia indication or the old antimalarial work. It’s the low-dose electron-cycling story, and thats worth taking seriously.

Here’s the mechanism as best we understand it: at low doses, methylene blue acts as an electron donor to Complex III of the mitochondrial electron transport chain, bypassing dysfunctional Complex I and Complex II. For conditions where mitochondrial dysfunction is upstream of neurodegeneration, that’s a genuinely useful probe mechanism, not a hand-wavy “supports mitochondria” claim. The Gonzalez-Lima group at UT Austin has published the most credible low-dose cognitive work, documenting improvements in rodent models of TBI, aging, fear extinction, and memory consolidation. The compound also appears to inhibit tau aggregation through a separate pathway, which is what pulled it into the Alzheimer’s space as a therapeutic candidate and gave it a second mechanistic identity worth tracking independently.

Dose-dependence here is important and a bit tricky to work around experimentally. High doses produce MAO inhibition and real serotonin syndrome risk, which complicates stack protocols and confounds signal if youre not careful about where you sit on the curve. Low-dose experiments need to be precisely calibrated. The blue staining effect on tissues and excreta is cosmetically obvious and can unmask participant blinding in clinical trials, a methodological headache that’s shown up more than once in the published discussion sections.

On the clinical side: the TauRx program used leucomethylthioninium, a reduced form, in phase 2 and phase 3 Alzheimer’s trials. Phase 2 signal was real and drew serious attention. Phase 3 confirmation was inconsistent. That outcome puts methylene blue in a familiar position: multi-lab preclinical is solid, small-N human cognitive signal exists but is modest, and replication is still genuinely in progress across several independent groups.

What we actually like here is the bench utility. Methylene blue is cheap, readily sourced at pharmaceutical grade, and provides a clean pharmacological tool for probing mitochondrial redox biology. If you’re building experiments around mitochondrial dysfunction in neurodegeneration, this belongs in the toolkit. We don’t think it’s a frontier compound, and we don’t think the cognitive signal is anywhere near settled. But it earns its place as a niche probe with a real mechanistic story and a well-characterized profile that makes it genuinely useful as a research instrument.

Novelty

40

Mechanism promise

65

In-category differentiation

55

Evidence quality

50

Translational signal

45

Research bench value

65

Rationale Ancient compound elevated by a mechanistically credible low-dose electron-donor story; preclinical is multi-lab and solid but the human cognitive signal remains modest and contested, placing it firmly in niche-probe territory rather than the novel-frontier tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenothiazine dye / electron donor

A phenothiazine dye used historically as an antimalarial and methemoglobinemia treatment, with mitochondrial electron-cycling activity at low doses for cognitive applications.

Abstract

Methylene blue (methylthioninium chloride; CAS 61-73-4; molecular formula C16H18ClN3S; molecular weight 319.85) is a phenothiazine dye with the longest pharmaceutical history of any synthetic compound (first synthesized 1876). The compound is FDA-approved for methemoglobinemia (high-dose, 1-2 mg/kg IV) and has historical use as an antimalarial. Low-dose methylene blue (0.5 to 4 mg/kg orally) has been studied for cognitive enhancement, traumatic brain injury, and Alzheimer disease, based on the compound’s mitochondrial electron-cycling activity (donates electrons to Complex III, bypassing dysfunctional Complex I/II). Pharmacology is complex and dose-dependent; high doses produce MAO inhibition and serotonin syndrome risk. Low-dose cognitive applications use 5 to 20 mg orally. The compound stains tissues and excreta blue, which is cosmetically obvious but harmless.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-122Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Kisspeptin

Plain-language summaryIntrigue 86 / 100

Kisspeptin is a hypothalamic neuropeptide that triggers GnRH release. It is the master regulator of puberty and reproductive hormones. Investigated for anovulatory infertility, hypogonadism, and reproductive disorders. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

58/100

Canonical KISS1R probe with strong human translation but limited novelty after two decades of characterization

Kisspeptin’s story starts in 2003, when loss-of-function KISS1 mutations were identified as the cause of idiopathic hypogonadotropic hypogonadism. That was genuinely exciting science. A single neuropeptide turned out to be the master switch for GnRH neuron firing, controlling puberty onset, menstrual cyclicity, the whole reproductive axis. The mechanism is clean and the biology is unambiguous: KISS1R agonism drives pulsatile GnRH release, which drives LH and FSH, which drives gonadal function. We like that story a lot.

What we dont like, from a research-merit standpoint, is that this story is now over 20 years old. The Cambridge group and others have done extensive characterization. Multiple groups have replicated the GnRH axis response across populations and experimental conditions. The mechanism is not in dispute. Thats actually the problem for novelty scoring. When the mechanism is settled and the primary application is the obvious one, you’re not on the frontier anymore.

Where kisspeptin remains genuinely useful is as a research tool for studying GnRH neuron dynamics. If your program involves hypothalamic neuroendocrinology, including puberty timing, functional hypothalamic amenorrhea, or energy-sensing crosstalk with the reproductive axis, kisspeptin is the canonical probe. There’s no replacement for it in that role. The kisspeptin-10 fragment is particularly useful for controlled, short-duration axis stimulation experiments where you want a tight pharmacokinetic window.

The fertility application is real and worth knowing. Several groups, including the London group with Lim et al. leading much of the clinical work, have explored kisspeptin-54 as an ovulation trigger in IVF. The OHSS-reduction angle has genuine rationale: because kisspeptin acts upstream through endogenous GnRH rather than exogenous LH, there’s a theoretical and some empirical advantage in high-responder populations. Effect size is real in the published trials. But we’re looking at phase 2 data, modest N, and a therapeutic problem that already has multiple established solutions. A phase 3 program is what’s needed to move this forward, and thats not there yet.

The emerging data on extrareproductive kisspeptin signaling, including metabolic effects, mood, and some interesting fMRI work on social bonding responses, adds a layer of interest. But these are exploratory signals, not yet a research program most labs would build around kisspeptin specifically. Honestly, this scores where it does because it’s a real neuropeptide with well-replicated human pharmacology and solid probe value in its domain, but the primary biology is settled and the clinical development path is narrow.

Novelty

45

Mechanism promise

55

In-category differentiation

65

Evidence quality

60

Translational signal

65

Research bench value

65

Rationale Kisspeptin is the master upstream regulator of the GnRH axis with well-replicated human pharmacology, scoring solidly on differentiation and translational signal as the canonical KISS1R probe; novelty is genuinely low after 20 years of active characterization, pulling the overall into the established-active tier rather than the frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Hypothalamic neuropeptide / KISS1R agonist

An endogenous neuropeptide encoded by the KISS1 gene, master regulator of GnRH neuron firing and reproductive function.

Abstract

Kisspeptin (kisspeptin-54 and shorter active fragments including kisspeptin-10; encoded by the KISS1 gene) is an endogenous peptide identified in 2003 as the master regulator of GnRH neuron firing in the hypothalamus, controlling reproductive function and pubertal onset. Loss-of-function mutations in KISS1 or its receptor KISS1R produce hypogonadotropic hypogonadism. Exogenous kisspeptin administration stimulates LH and FSH release through GnRH neuron activation. The compound has been studied as a fertility therapeutic (induction of ovulation in functional hypothalamic amenorrhea) and as a research probe for reproductive neuroendocrine function. Pharmacokinetics: plasma half-life of kisspeptin-54 is ~30 minutes; kisspeptin-10 has shorter half-life. Research doses are highly variable; clinical trial doses range 0.01 to 6.4 nmol/kg IV.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-138Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Magnolia Bark (Honokiol/Magnolol)

Plain-language summaryIntrigue 50 / 100

Magnolia bark contains the biphenyl compounds honokiol and magnolol, which positively modulate GABA-A receptors and produce mild anxiolytic and sleep-promoting effects. Used in traditional Chinese medicine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Mature botanical anxiolytic with an interesting non-benzo GABAergic angle but thin human evidence and no clear edge over alternatives

Look, magnolia bark has been a fixture in traditional Chinese medicine for centuries, and the active constituents, honokiol and magnolol, have accumulated a solid if unspectacular literature over the past few decades. What we find genuinely interesting here is the mechanism: both biphenyls act as positive allosteric modulators at GABA-A receptors, but through a binding site distinct from the classical benzodiazepine site. Thats not nothing. The neurosteroid-adjacent binding pocket is an active area of inquiry, and compounds that engage it without benzo-site pharmacology are worth watching in anxiolytic research.

Here’s the thing though. This is a botanical extract, which means you’re working with a mixture of honokiol and magnolol in variable ratios depending on sourcing, extraction method, and batch. That matters enormously for any serious bench work. The preclinical literature largely uses isolated honokiol or isolated magnolol, not standardized bark extract, so translating rodent data to an extract formulation introduces real uncertainty about which constituent is driving which effect and at what concentration.

The evidence base is multi-lab at the preclinical level. Several groups have confirmed GABAergic activity for both compounds in rodent behavioral models, and honokiol’s NF-kB inhibitory activity shows up across independent labs as well. What’s missing is solid human clinical data. The few small human trials that exist report modest anxiolytic and sleep-promoting effects, but nothing that would move the needle for a serious investigator. Effect sizes are small, N is small, and replication is thin. Honestly, the human signal is closer to preliminary than compelling.

Differentiation is a real problem. In the botanical anxiolytic space, magnolia bark competes with kava (which has a cleaner human evidence base for anxiolysis), ashwagandha (which has multiple reasonably-designed trials behind it), and passionflower (which hits overlapping GABAergic targets). There’s no dimension where magnolia bark clearly outperforms the field. The non-benzo binding site is interesting in principle, but if you need a clean probe for that site, you’d reach for a neurosteroid analog or a well-characterized synthetic tool, not an herbal extract with batch-to-batch variability.

What we’d say to a bench investigator: isolated honokiol, not the bark extract, could have real probe value in the narrow context of GABA-A PAM research outside the benzo site. As a botanical formulation, its hard to use rigorously, the human evidence is underwhelming, and the anxiolytic space is crowded with better-characterized alternatives. Not the worst entry in the library. Not interesting enough to prioritize over the compounds where the evidence and novelty actually line up.

Novelty

28

Mechanism promise

42

In-category differentiation

32

Evidence quality

35

Translational signal

28

Research bench value

35

Rationale The non-benzodiazepine GABA-A PAM binding site earns mechanism credit, but extract-format variability, a crowded botanical anxiolytic field, and underwhelming human clinical data drag every other axis down; calculated overall of 33 sits below the OTC herb cap so no cap binds.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Botanical with biphenyl active constituents

Bark of Magnolia officinalis containing the biphenyl compounds honokiol and magnolol with anxiolytic and sleep-promoting activity through GABAergic mechanisms.

Abstract

Magnolia bark (Magnolia officinalis bark) contains the biphenyl compounds honokiol and magnolol as the principal active constituents. Both compounds show GABA-A receptor positive allosteric modulation through binding sites distinct from the benzodiazepine site. Honokiol additionally shows anti-inflammatory and antioxidant activity through NF-kB inhibition and direct radical scavenging. The compound has been studied for anxiety, sleep, and inflammatory conditions. Doses are typically 200 to 500 mg of standardized bark extract per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-154Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Esketamine

Plain-language summaryIntrigue 82 / 100

Esketamine, sold as Spravato, is the S-enantiomer of ketamine purified out as a single isomer. Approved in 2019 as an intranasal spray for treatment-resistant depression. About twice as potent as racemic ketamine at NMDA receptors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

61/100

FDA-approved rapid antidepressant with live mechanistic debate around stereochemistry and HNK metabolite signal

Look, esketamine occupies a strange position in a research library. It’s an FDA-approved Schedule III drug with a real REMS program, multiple Phase 3 RCTs behind it, and the only formal regulatory endorsement in the rapid-acting antidepressant class. That’s legitimate standing. But the question for bench investigators is whether the compound is still generating new science, or whether the interesting questions have migrated somewhere downstream and esketamine is now mostly a clinical asset with a closed mechanistic story. The honest answer is: it’s somewhere in between.

The still-live science centers on mechanism. Whether the antidepressant effect comes from direct NMDA channel block, downstream AMPA potentiation, or the (2R,6R)-hydroxynorketamine metabolite that may bypass NMDA entirely is genuinely unresolved. The Zanos et al. 2016 Nature paper on HNK sparked a real fight that hasnt been settled, and esketamine is relevant to that fight precisely because its stereospecificity lets investigators parse contributions that racemic ketamine muddles. If you’re working on rapid-antidepressant mechanism, enantiomeric comparisons between S- and R-ketamine give you a probe you can’t replicate with the racemate.

The differentiation case is complicated. Esketamine has the FDA stamp and standardized intranasal delivery, but IV racemic ketamine is still widely used off-label, often preferred clinically because of cost and dosing flexibility. More pressingly, the emerging R-ketamine story from the Hashimoto lab argues that the R-enantiomer may produce antidepressant effects without dissociation, which if confirmed would directly challenge esketamine’s clinical position and make the stereochemistry question more urgent for research programs, not less.

Evidence quality is solid. The TRANSFORM and SUSTAIN trial programs gave esketamine multiple Phase 3 wins, and real-world post-approval data is accumulating. The methodological criticisms are legitimate, the open-label responder enrichment designs took pointed criticism at the FDA advisory committee level, but the compound cleared the bar and is being used on patients with treatment-resistant depression. That’s real translational signal, specifically in a population where alternatives are genuinely exhausted.

Where the score pulls back is novelty and conditional bench utility. Ketamine pharmacology has been in the literature since the 1960s. If your research question is not specifically about stereochemistry, enantiomeric dissociation, or NMDA-independent rapid antidepressant pathways, esketamine doesn’t open doors the racemate hasn’t already touched. What we like: unresolved mechanistic questions, enantiomeric probe specificity, FDA-validated clinical effect in a hard population. What we dont like: REMS overhead for research access, and the sense that the frontier has moved toward HNK and downstream plasticity targets rather than the parent compound itself.

Novelty

40

Mechanism promise

65

In-category differentiation

58

Evidence quality

70

Translational signal

75

Research bench value

65

Rationale Novelty is limited by decades of ketamine literature, but esketamine earns real points for FDA approval, well-documented Phase 3 evidence, and the genuinely unresolved mechanistic fight over whether the antidepressant signal traces to NMDA block, AMPA potentiation, or the (2R,6R)-HNK metabolite. Score reflects an established compound with meaningful bench utility for stereochemistry and rapid-antidepressant mechanism research, pulled back by REMS overhead, aging underlying pharmacology, and a research frontier that is visibly migrating toward metabolite biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

S-enantiomer NMDA antagonist

The (S)-enantiomer of ketamine, FDA-approved as Spravato (intranasal) for treatment-resistant depression.

Abstract

Esketamine (Spravato; CAS 33643-46-8) is the (S)-enantiomer of ketamine, FDA-approved in 2019 as an intranasal formulation for treatment-resistant depression and as adjunctive treatment for major depressive disorder with acute suicidal ideation (2020). The (S)-enantiomer carries higher NMDA receptor affinity than the (R)-enantiomer; the racemic ketamine is approximately 60 percent (S)-enantiomer activity. Pharmacokinetics: intranasal bioavailability ~48 percent; plasma half-life 7 to 12 hours. Approved doses are 56 to 84 mg intranasal twice weekly initially, tapering. Schedule III. REMS distribution program due to dissociation and abuse risk.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-171Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 46 47 48 49 50 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.